Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT Sequential Capecitabine vs Capecitabine in Early-Stage High-Risk TNBC
NCT07628504Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in triple negative breast cancer (TNBC), sponsored by Fudan University. Planned start May 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07628504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628504.